Investing requires insights from top analyst reports—authoritative, professional, timely, and comprehensive—to help uncover promising thematic opportunities!

The brain-computer interface (BCI) concept erupted in a wave of limit-up gains; how can investors identify potential stocks within this theme that still have room for catch-up growth? From the batch of BCI concept stocks hitting their daily upside limits in Monday's A-share market, it is evident that capital is flooding into this currently hottest investment trend. Notably, Hangzhou, as a national innovative city and a hub for the digital economy, has established significant industrial advantages and an innovative ecosystem in the BCI field.

The first trading day of 2026 in the A-share market was dominated by the explosive surge of the BCI concept. Ranking first among all conceptual sectors by closing gains, the BCI板块 far outperformed others with an average sector increase of 12.16% on Monday—truly in a league of its own. Catalyzing this move, during the New Year's market closure, the world's richest person, Elon Musk, announced on social media platform X that his BCI company, Neuralink, will commence mass production of BCI devices in 2026, concurrently advancing fully automated surgical procedures. With Musk providing a clear mass-production timeline, this cutting-edge sector is accelerating its transition from laboratory exploration to commercial application, marking a critical turning point for the industry's evolution from "medical experimental products" to "mass-market consumer goods." Against this backdrop, BCI concept stocks in the A-share market have entered a euphoric phase, not only leading all sectors in gains but also setting a historic record for the number of individual stocks hitting their daily limit-ups! Specifically, stocks like Innovation Medical (002173), Yanshan Technology (002195), Sanbo Medical (301293), Meihao Medical (301363), and Nanjing Panda (600775) opened with direct limit-up "一字板" gains, igniting market-wide enthusiasm. This was followed by a batch of other BCI concept stocks—including Intretech (002925), Xiangyu Medical (688626), Aipeng Medical (300753), Saili Medical (603716), Beiyikang (920199), Shangji Technology (301330), Weisi Medical (688580), and Chengyitong (300430)—also sealing their daily limit-ups! By Monday's close, over 50 BCI concept stocks had surged by the daily limit or gained more than 10%, with over 20 of these seeing 20CM limit-ups. Clearly, major capital is rushing headlong into BCI, currently the most explosive trend in the A-share market.

Musk strikes again: 2026 will usher in the era of mass production for brain-computer interfaces! BCI concept stocks in the A-share market have entered a狂欢模式: capital is pouring in疯狂地, with the sector's average gain reaching 12.16% on Monday, far领先其他板块—truly "一骑绝尘"! The batch limit-ups of BCI stocks signal that the sector has rapidly become the hottest风口 in the current A-share market.

It must be said that the immediate trigger for this comprehensive surge in BCI概念 stocks was the latest developments from Musk's BCI giant, Neuralink. On January 1, local time, Musk announced on social media that Neuralink will begin mass production of BCI devices in 2026 and advance nearly fully automated surgical procedures. Simultaneously, Merge Labs, backed by OpenAI CEO Sam Altman, is spinning off independently to focus on a new technological approach using ultrasound to read brain activity. The moves by these two tech giants indicate that the BCI赛道 is transitioning from singular scientific experimentation to diversified commercial competition.

Brain-computer interface, as the name implies, is a communication channel connecting the human brain with computing devices. Specifically, it involves collecting neural signals from the brain via electrodes, decoding them through algorithms into executable commands for devices, while also transmitting external stimuli back to regulate brain activity.

Currently, based on the method of signal acquisition and the degree of brain implantation, BCI can be categorized into three types: invasive, semi-invasive, and non-invasive.

The BCI industry has now formed a complete industrial chain, encompassing upstream (materials, chips, electrodes, etc.), midstream (signal acquisition and processing, etc.), and downstream (medical health, consumer life, industrial production, etc.) segments.

Musk's Neuralink, founded in 2016, aims to enable people to control computers directly via neural signals through a coin-sized brain chip. The company is a典型代表 of the global invasive BCI technological pathway; its devices insert electrode threads directly through the dura mater without requiring incision, implying minimal trauma.

Currently, Neuralink's brain implants primarily target patients with neurological disorders like spinal cord injuries. According to company disclosures, as of September 2025, 12 severely paralyzed patients globally have received Neuralink implants, with recipients able to perform tasks such as playing games, browsing the internet, and posting on social media. This marks a实质性突破 in restoring basic communication and environmental control capabilities.

Musk also expressed hopes of achieving a "whole-brain interface plan" by 2028, integrating the human brain comprehensively with AI for consciousness-level interconnection. According to Musk's product roadmap, future developments will cover motor decoding (mainly for patients with movement disorders like spinal cord injuries and ALS), visual encoding (for the visually impaired), and an ultimate device called "Deep" capable of inserting electrodes into any brain region to treat mental illnesses, pain, and other neurological conditions.

With Musk recently providing a clear mass-production timeline for BCI devices, this前沿赛道 is accelerating from laboratory scientific exploration toward commercial落地, undoubtedly approaching a关键转折点 for the industry's leap from "medical experimental products" to "mass-market consumer goods."

Kaiyuan Securities noted in its latest research report that Neuralink's mass-production expectations and automated surgical solutions hold dual milestone significance. This not only signals BCI's transition from a "medical experimental tool" to a "scalable product" but also lays the foundation for future synergistic applications with Tesla's Optimus humanoid robots.

In fact, early last year, the National Healthcare Security Administration's guidelines on BCI rehabilitation pricing directly accelerated the rapid development of China's BCI industry. Approximately 11 provinces and cities have now issued relevant pricing standards, with many companies also disclosing latest commercial progress.

2025 is regarded by the industry as the inaugural year for "brain-computer interfaces" in China. On the policy front, the "15th Five-Year Plan" recommendations explicitly list "brain-computer interface" as one of six key future industries for focused development.

Specifically, the National Healthcare Security Administration's "Guidelines for Establishing Medical Service Price Items for the Nervous System," released in March last year, created separate pricing items for BCI新技术, including fees for non-invasive BCI adaptation, invasive BCI implantation, and explantation. This is viewed externally as a key policy driver for the BCI industry.

In September 2025, the National Healthcare Security Administration introduced new regulations明确 opening a "green channel" for医保赋码 of innovative medical products like BCI, further accelerating clinical practice and application.

Additionally, seven departments including the Ministry of Industry and Information Technology previously issued the "Implementation Opinions on Promoting the Innovative Development of the Brain-Computer Interface Industry." These propose that by 2027, China will achieve breakthroughs in key BCI technologies, initially establishing advanced technical, industrial, and standard systems. Furthermore, BCI products will see accelerated application, the industry scale will continuously expand, and 2 to 3 industrial development clusters will be created. Meanwhile, since 2025, regions like Beijing, Shanghai, Sichuan, and Shandong have successively introduced policy documents focusing on BCI innovation and development, providing safeguards for the industry's rapid growth.

Behind this迅猛 industrial development, China's BCI field has also witnessed continuous breakthroughs in key technologies and clinical applications.

In June last year, the Chinese Academy of Sciences Center for Excellence in Brain Science and Intelligence Technology, in collaboration with Huashan Hospital affiliated with Fudan University and relevant enterprises (Ladder Medical), successfully conducted China's first invasive clinical trial, marking China as the second country globally to enter the clinical trial stage for invasive BCI technology.

Furthermore, in October 2025, the "Beinao-1" GCP multi-center clinical trial officially launched—the world's first semi-invasive BCI system achieving over 100 channels, high throughput, fully implanted wireless capability, and quasi-practical application. China Post Securities stated that this标志着 China's BCI research is entering a new stage of standardized, large-scale clinical validation.

It is worth noting that regarding the BCI industry, the gap between China and advanced overseas technologies is not large, and China is already within the first tier.

Domestic companies have made significant progress in specific areas. BrainCo's independently developed 256-channel high-throughput implantable flexible BCI marks China's world-leading level in this field. In the non-invasive domain, StrongBrain Technology has launched a C-end intelligent sleep aid device, while companies like Chengyitong and Xiangyu Medical plan to apply the technology in anesthesia monitoring and medical rehabilitation.

Beyond medical necessities, BCI is seen as the key to unlocking the ultimate form of human-machine collaboration.

Kaiyuan Securities analysis suggests the BCI industry is expanding from medical rigid demand into AI applications, robotics, and other fields. Musk has explicitly stated that with future Neuralink technological upgrades, it may be possible to remotely control Optimus robots via意念, constructing an ultimate ecosystem of "human brain + robot."

According to Precedence Research data, the global BCI market size is projected to grow to approximately $12.4 billion by 2034, with a compound annual growth rate of 17% from 2025 to 2034. Morgan Stanley further predicts the market size could leap to $320 billion by 2045.

CSC Financial believes that multiple favorable policies introduced at the national and regional levels are driving rapid industry development, with the recent National Healthcare Security Administration document establishing separate pricing for BCI新技术. Catalyzed by technological innovation and policy红利, domestic BCI companies are expected to gradually achieve commercial applications.

Against this broad backdrop, BCI concept stocks in the A-share market have entered a狂欢模式, not only leading all sectors in gains but also setting a historic record for the number of individual stocks hitting their daily limit-ups!

By Monday's close, over 50 BCI concept stocks had surged by the daily limit or gained more than 10%, with over 20 of these seeing 20CM limit-ups! Clearly, major capital is rushing headlong into BCI, currently the most explosive trend in the A-share market.

It is reported that Aupu Technology's main business covers intelligent control system integration, home appliance manufacturing, and medical device sales. Notably, the company is located in Hangzhou, a core hub for China's BCI technology, home to top research institutions like Zhejiang University and global leaders like StrongBrain Technology, positioning it at the international forefront in non-invasive technology and medical rehabilitation applications.

As a national innovative city and a digital economy highland, Hangzhou has formed significant industrial advantages and an innovative ecosystem in the BCI field. Leveraging high-level platforms like "China Visual Valley," Hangzhou focuses on future industry layout, promoting the transition of BCI technology from laboratory to industrial application through policy support, enterprise clustering, and scenario innovation.

The Hangzhou municipal government introduced special measures in 2025明确 supporting the BCI and neuromorphic computing fields, covering three major directions: R&D innovation, industrial clustering, and ecosystem building. Specific policies include:

R&D Innovation Support: Projects undertaking national or provincial key science and technology programs receive subsidies of up to 5 million yuan, covering 25% of actual received funds; enterprises with R&D expenditure increases exceeding 2 million yuan or total R&D exceeding 100 million yuan receive subsidies of up to 2 million yuan, covering 5% of the increment.

Industrialization and Talent Incentives: Newly规上 enterprises receive rewards of up to 200,000 yuan; products newly obtaining Class III medical device registration certificates are rewarded up to 1 million yuan; efforts to cultivate and attract neuromorphic intelligence talent are strengthened.

Industrial Ecosystem and Enterprise Clustering: Hangzhou has attracted a cluster of BCI enterprises. Besides StrongBrain Technology, examples include: Westlake Lingxi Technology: self-developed 256-channel BCI chip, with 40nm process power consumption领先 Neuralink, achieving real-time Korean language brain-speech reconstruction in 2025. Manan Intelligence: focuses on non-invasive BCI technology, developing brain-controlled wheelchairs and autism intervention products, promoting application in medical health. Mailian Technology, Donghong Technology, Nuanxinjia, and Xingyuan Intelligence have achieved breakthroughs in closed-loop neural modulation, visual BCI products, and other细分赛道. These enterprises, leveraging the "China Visual Valley" ecosystem, collaborate on hardware R&D, algorithm optimization, and scenario implementation.

Technological Progress and Application Scenarios: Hangzhou's BCI technology continues to break through, such as improved stability of multi-channel BCI chips and optimized AI decoding accuracy, supporting real-time decoding of fine motor intentions. Application scenarios cover medical rehabilitation, health wellness, and educational intervention.

Driven by Zhejiang's "15th Five-Year Plan," Hangzhou is strengthening the construction of a neuromorphic intelligence future industry pilot zone with a "one core, two wings" layout, accelerating the integration of BCI with industries like intelligent transportation and medical health, and building a full-chain ecosystem from R&D to commercial application.

Notably, as a locally listed company in Hangzhou, the company has invested in Hangzhou Jiali Medical Technology Co., Ltd., a heavyweight enterprise in the local BCI field. Public information shows that Hangzhou Jiali Medical Technology Co., Ltd. is a medical technology enterprise focused on BCI technology R&D. Its core product, Epilcure, is an implantable closed-loop neurostimulation system for treating drug-resistant epilepsy. The system provides precise treatment by实时 monitoring brainwaves and automatically intervening upon detecting abnormal signals.

Hangzhou Jiali Medical Technology Co., Ltd. owns three wholly-owned subsidiaries: Hangzhou Bolun Brain-Computer Technology Co., Ltd., Hangzhou Naoxin Technology Co., Ltd., and Hangzhou Nuowei Medical Technology Co., Ltd.

In March 2025, Jiali Medical, in collaboration with the Second Affiliated Hospital of Zhejiang University School of Medicine, and jointly with the Nanhu Brain-Computer Cross-Research Institute, the National Key Laboratory of Brain-Machine Intelligence, and the College of Biomedical Engineering and Instrument Science, completed China's first "closed-loop spinal cord neural interface" implant surgery.

This was a national first: a patient with complete paraplegia achieved autonomous standing and walking movements through the neural interface system. Jiali Medical's core product—the closed-loop neural modulation system Epilcure—is designed based on invasive BCI technology, capable of accurately identifying brain electrical signals and performing real-time responsive intervention.

Its main structure consists of the following key components: High-sensitivity potential acquisition and electrode array: Capable of capturing weak yet pure intracranial neural signals. Precise brainwave recognition algorithm: Used to parse complex brainwave patterns, such as identifying pre-seizure epileptic activity. Control chip: Responsible for internal signal processing and control logic. Efficient output stimulation system: Precisely modulates and intervenes in the nervous system based on recognition results.

Jiali Medical CEO Cao Peng特别 emphasized Epilcure's design advantages. The system utilizes wireless charging technology, greatly facilitating patients' daily use and significantly extending the device's service life.

Additionally, the innovative full-skull implantation method is considered to "reduce the risk of infection and electrode breakage," showing better performance in surgical tolerance and safety compared to some foreign products.

Reportedly, Epilcure has completed over one hundred clinical implants in several top hospitals, including Beijing Xuanwu Hospital.

Currently, multi-center clinical trials nationwide are still intensively ongoing. Jiali Medical's goal is to "complete follow-ups for all patients in 2025 and plan to obtain the Class III medical device product registration certificate in 2026," thereby achieving formal commercial launch of the product to benefit more patients.

Beyond breakthroughs in epilepsy treatment, Jiali Medical has also demonstrated practical application cases in the direction of paraplegia.

In March 2025, China's first 'closed-loop spinal cord neural interface' implant surgery embodied years of Jiali Medical's technical accumulation in the BCI field. The system integrates a 16-contact stimulation electrode, a fully implantable rechargeable spinal cord stimulator, a wireless EMG signal acquisition device, and self-developed modulation software, possessing capabilities for precise electrical stimulation output, flexible contact configuration, and closed-loop feedback regulation.

Jiali Medical possesses independent innovation capabilities, having applied for nearly 200 patents cumulatively and obtained over 100 authorizations, including 30 PCT patents.

Jiali Medical has built three前沿 technology lines centered on BCI and extending to laser ablation and neural modulation. The company collaborates closely with top domestic universities and medical institutions to jointly promote technological innovation and clinical application.

Currently, Jiali Medical's BCI device for drug-resistant epilepsy has made progress, with applications for Parkinson's disease and paraplegia also entering the clinical trial stage.

Its core products include the magnetic resonance-guided laser ablation surgical system LaserRO, which precisely ablates foci of epilepsy, brain tumors, etc., via minimally invasive methods. It has completed enrollment for confirmatory clinical trials and shown good efficacy.

Another core product is the implantable closed-loop neural modulation system Epilcure. As Asia's first reactive neurostimulation system achieving human implantation, it is based on brain-computer interaction technology, providing personalized on-demand treatment for epilepsy patients through continuous monitoring and reactive electrical stimulation, while also supporting remote consultation.

Both innovative products have passed the special review procedure (innovation channel) of the Medical Device Technology Evaluation Center of the National Medical Products Administration.

Jiali Medical indicated that 2025 will be a key node for its product registration and the initiation of its internationalization strategy.

Looking ahead, the company will also actively explore the deep integration and落地 of BCI technology with rehabilitation robots and elderly assistive devices. As CEO Cao Peng展望 in an interview, "In the next 5 to 10 years, with the support of BCI, home-based intelligent robots are expected to better assist the elderly in daily activities, realizing the vision of 'not only treating diseases but also controlling external devices'."

According to public information, the company holds a 4.32% stake in Hangzhou Jiali Medical Technology Co., Ltd. through Hangzhou Haibang Shurui Equity Investment Partnership (Limited Partnership).